Aspira Women's Health Secures Reimbursement For Ova1Plus From California Medicaid; Reimbursed At Rate Of $897 For All Ova1Plus Tests Meeting Applicable Coverage From Oct. 15, 2023.
Portfolio Pulse from Benzinga Newsdesk
Aspira Women's Health has obtained reimbursement approval for its Ova1Plus test from California Medicaid. The test will be reimbursed at a rate of $897 for all tests meeting the applicable coverage criteria, effective from October 15, 2023.
November 28, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aspira Women's Health's Ova1Plus test has been approved for reimbursement by California Medicaid at a rate of $897, which may lead to increased revenue from this coverage.
The approval for reimbursement from California Medicaid is a significant positive development for Aspira Women's Health, as it not only validates the Ova1Plus test but also opens up a new revenue stream. The reimbursement rate of $897 per test is substantial and, assuming the tests meet the coverage criteria, this could lead to an increase in the number of tests administered and billed to Medicaid, thereby potentially increasing the company's revenues in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100